Branded Legacy Announces Leadership Overhaul and Strategic Merger to Enter Addiction Therapeutics Market
July 14th, 2025 6:15 PM
By: Newsworthy Staff
Branded Legacy (OTC: BLEG) undergoes a complete leadership change and plans a merger with a company specializing in intranasal drug delivery, aiming to innovate in the addiction treatment sector with projected first-year revenues of $40 million.
Branded Legacy (OTC: BLEG) has announced a significant leadership transition and a strategic merger aimed at positioning the company within the addiction therapeutics market. Interim CEO Jeffery Robison has taken the helm following the resignation of the previous management team. The company has submitted a Letter of Intent for a merger with a firm that specializes in advanced intranasal drug delivery technologies, including a patented naloxone device designed to combat opioid overdoses.
The merger, expected to close within two weeks pending necessary approvals, is projected to generate $40 million in revenue in its first year. This move represents Branded Legacy's ambitious plan to introduce scalable and cost-effective solutions to the opioid overdose and broader addiction treatment markets. The merger underscores the company's commitment to innovation and strategic growth in the biotech and wellness sectors.
For further details on the announcement, visit https://ibn.fm/TmW7Q.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
